Current status
Hair cloning is not an approved treatment. Current research includes at least two distinct development tracks: cultured follicular cells intended to strengthen existing miniaturising follicles, and engineered follicular units intended to create additional hairs.
Follicular-cell rejuvenation is the more clinically advanced category. HairClone has reported preparations for autologous follicle-cell injections in Guatemala. The registered EPI-001 Phase I/II study is recruiting participants to test autologous dermal papilla cells in South Korea. Neither programme has established an approved treatment.
Technical requirements for new follicles
A functional hair follicle is a miniature organ. It must form the appropriate cellular architecture, grow in the correct direction, connect with surrounding tissue and continue cycling. Hair-shaft production in a laboratory or animal model does not establish cosmetically reliable human scalp coverage.
OrganTech’s 2026 work identified an additional supporting mesenchymal population in an in-vitro regeneration system. The finding indicates that regeneration may require coordinated interaction among several cell populations.
Evidence classification
We classify follicular-cell rejuvenation as early clinical and dependable de novo follicle creation as preclinical. Human studies and commercial follicle banking are under way, but there is no completed pivotal evidence package for follicle cloning and no approved product in a major regulated market.
Relevant future evidence includes reproducible human hair-count data, durability beyond one full cycle, safety follow-up, manufacturing consistency and publication of protocols and results.